Remove Clinical Trials Remove Patients Remove Presentation
article thumbnail

AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591

Cannabis Law Report

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Abstract Number: 5015.

Data 100
article thumbnail

1 in 5 Parkinson’s Patients Use Cannabis

CannaMD

In a paper presented at the 2020 International Congress of Parkinson’s Disease and Movement Disorders , the authors reported on the results of an anonymous survey completed by more than 1,000 individuals living with Parkinson’s disease. Why Do Parkinson’s Patients Use Marijuana? Patients Need More Marijuana Info.

Patients 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cannabis Helps, Say Over Half of Parkinson’s Patients Who Use It

The Cannigma

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.

Patients 107
article thumbnail

Clinical Trial Finds Marijuana Oil to be Effective in Treating Fibromyalgia

The Joint Blog

According to a new study published in the journal Pain Medicine and epublished by the National Institute of Health, the daily use of marijuana oil is effective and well-tolerated among patients with fibromyalgia. On average patients received 3.6 Placebo controlled patients received no such benefit. mg of THC and 0.08

article thumbnail

THC & CBD-Rich Cannabis for Fibromyalgia

Project CBD

Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life. No single drug yet exists to address all of the disease’s effects on the body, which can include widespread aches and pains, sleeplessness, fatigue, anxiety, and depression.

THC 144
article thumbnail

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Cannabis Law Report

IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

article thumbnail

European Regulatory Lead MAPS PBC Santa Cruz, CA

Cannabis Law Report

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. The right candidate will have a passion for clinical research in novel therapeutics and a proven track record of regulatory affairs experience. Key Responsibilities.